申请人:Takeda Chemical Industries, Ltd.
公开号:US05496834A1
公开(公告)日:1996-03-05
The present invention provides novel compound of the formulas (Ia) or (I): ##STR1## wherein Q is one or two amino acid residues which may be substituted; R.sup.3 is a carboxyl group which may be esterified or an acyl group; A is an alkylene group; B is hydrogen or an alkyl group which may be substituted or an acyl group; or a salt thereof; ##STR2## wherein R.sup.1 and R.sup.2 may be the same or different and each is hydrogen or a hydrocarbon residue which may be substituted; R.sup.3, A and B have the same definitions as those shown above; m and n each is 0 or 1; provided that where both m and n are both equal to 0, R.sup.3 is a carboxyl group which may be esterified or an acyl group having not less than 7 carbon atoms; or a salt thereof. The compound (Ia) or (I) shows cathepsin L inhibitory and bone resorption inhibitory activities and are useful as a prophylactic/therapeutic agent for osteoporosis.
本发明提供了式(Ia)或(I)的新化合物:##STR1## 其中Q是一个或两个氨基酸残基,可以被取代;R.sup.3是一个羧基,可以被酯化或酰基化;A是一个烷基;B是氢或一个可以被取代的烷基或酰基;或其盐;##STR2## 其中R.sup.1和R.sup.2可以相同也可以不同,每个都是氢或可以被取代的碳氢残基;R.sup.3,A和B具有与上述所示相同的定义;m和n各自为0或1;但是,当m和n都等于0时,R.sup.3是一个羧基,可以被酯化或酰基化,具有不少于7个碳原子的酰基;或其盐。化合物(Ia)或(I)显示出抑制半胱氨酸蛋白酶L和抑制骨吸收的活性,并且可用作预防/治疗骨质疏松症的药物。